Page 19 - CIBERSAM2016-ENG

Schizophrenia
Coordinator: Julio Sanjuán Arias (Universidad de Valencia)
Some of the most notable results of the programme in 2016 that we could mention are the publication of 116 scientific articles, most of these (n=68; 59%) published in first quartile journals according to the Journal Citation Reports (JCR). It should be mentioned that 28 articles (23%) were published in first decile journals, mostly in the categories of Neurosciences and Psychiatry, and including Nature, Nature Neuroscience, JAMA Psychiatry, American Journal of Psychiatry, Cerebral Cortex, Neuroscience and Biobehavioral Reviews, and Schizophrenia Bulletin.
As regards projects carried out by the members of the programme, we should give special mention to
the participation of several CIBERSAM groups in European projects including: METSY, PSYSCAN, PRISM, m-RESIST; as well as obtaining financing in national competitive public calls (ISCIII and MINECO) and other regional ones. Over this year the Cohorts-CIBERSAM project financed by the ISCIII was got under way, with the participation of 13 CIBERSAM groups. We should also stress the proper development of both the CIBERSAM first episodes project (PEPs PI 080208), currently in the stage of exploiting the data and publishing this, and of the Integrated Projects of Excellence (ISCIII) (PIE14/0003) in the stage of completing the collection of samples and preliminary analyses.
Mention should also be given to obtaining Human Resources contracts: researchers in SNS Miguel Servet I (1; G11), Miguel Servet II (1; G15), Sara Borrell (1; G15), predoctoral training contract in research (ISCIII) (1; G15), Juan de la Cierva (1; G15), Juan Rodés contract (1; G01), Ramon y Cajal (1; G19) and Río Hortega Post Specialised Healthcare Training Contracts (1; G26).
The granting of 1 patent on nationwide level should also be mentioned.
The great presence of CIBERSAM groups in major international consortiums engaged in the investigation of genetic aspects (Psychiatric Genetic Consortium) and Neuroimaging-Genetics (ENIGMA) in schizophrenia is also an aspect to be stressed.
In 2016 we can highlight the development of impact research in the following lines:
• The development of clinical trials intended to display the effectiveness of non-pharmacological treatments in schizophrenia.
• Clinical research tackling clinical issues of relevance in the treatment and care of patients with schizophrenia.
• The study of the effects of antipsychotic medication on the physical health of patients.
• Cognition and schizophrenia: biological markers and therapeutic strategies.
• Study of the importance of inflammatory processes in schizophrenia and cognitive aspects.
• The study of metabotropic glutamate receptors and of the mGLu2/5-HT2A complex as potential objectives of new antipsychotic drugs.
• The search for (genetic and neuroimaging) biomarkers associated with the illness and specific clinical aspects from the initial stages of the illness.
SAM
Scientific Programmes 19